U.S. markets closed

CanaQuest Medical Corp. (CANQF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05830.0000 (0.00%)
At close: 12:04PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0583
Open0.0583
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0583 - 0.0583
52 Week Range0.0201 - 0.3000
Volume10
Avg. Volume3,473
Market Cap2.416M
Beta (5Y Monthly)3.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.
    GlobeNewswire

    CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.

    TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced a new production and distribution agreement with PurCann Pharma (“PurCann“) and SiliCycle Inc. (“SiliCycle“). PurCann, a subsidiary of SiliCycle, is recognized for its unique expertise in the Extraction-Purification and commercialization of cannabinoids. This agreement facilitates CanaQuest’s planned production, distribution and global export of Mentanine® and Mentabinol® formulations, through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License from Health Canada under the Cannabis Act. Initial sales are anticipated within 16 weeks after funding. Hugo St-Laurent, PurCann, President, stated, “Mentanine® and Mentabinol® perfectly align with our strategic objectives. CanaQuest can benefit from SiliCycle and PurCann’s robust Canadian distribution channels and also leverage our organization’s international pharmaceutical health product marketing expertise across more than 100 countries.“ Paul Ramsay, CanaQuest Co-Founder & President, added, “We are extremely pleased to have PurCann Pharma, a Health Canada Licenced Processor and its parent company SiliCycle as new partners for our medicinal formulated products rollout, reflecting their exceptionally high pharma quality standards, expertise and processing capabilities.“ CanaQuest - Commercial Ready Master Formulations:Mentanine®, Omega-3 + CBD based formulation, non-psychotic – increases the efficacy of CBD at a specific nuclear receptor in the brain, for the treatment of mental ailments. The formulation interacts with the Central Nervous System "CNS" that controls anxiety, depression, schizophrenia, Post Traumatic Stress Disorder “PTSD”, and addiction. Additionally, the improved efficacy (sublingually delivered) requires substantially smaller doses of CBD, thus, eliminating or minimizing existing liver toxicity caused by high oral consumption of CBD (as noted in a recent FDA comment). Mentabinol®, THC based formulation & L-theanine - a safer alternative, for people who are taking THC for mental ailments, chronic pain, chemotherapy side-effects or for reducing anxiety or depression. The formulation could also be a viable treatment for opioid addiction. Both formulations, are scientifically developed and proven by pre-clinical trials at Western University by a scientific team lead by Dr. Steven Laviolette. About CanaQuest Medical Corp: CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx and Mentabinol®Rx in Canada and the USA. As well, CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council. For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDgFor more information on CanaQuest, visit http://www.canaquest.com About SiliCycle: SiliCycle Group is a world leader in the development, manufacturing, and marketing of specialty products for the pharmaceutical and health sciences industry. A technical expert in fine chemistry, SiliCycle’s Group sells its solutions in the extraction and purification of molecules of interest and in silica chemistry in more than 100 countries. SiliCycle Group's know-how is sought after by major industrial manufacturing companies, including analytical laboratories, pharmaceutical, cosmetic, nutraceutical, food companies and academic laboratories around the world. The members of the SiliCycle Group are technology companies specializing in research and development and in the manufacture of products and services dedicated to health, well-being and the reduction of environmental impacts for its global clientele. It includes the following divisions and subsidiaries: SiliCycle (Chromatography products, Synéova, YuLife)PurCann PharmaAkua NatureGbrTotal OceanPharma in silicaMirapakonRV2 Technologies For more information on SiliCycle, visit https://www.silicycle.com/ca/about-silicycle About PurCann Pharma: PurCann Pharma is specialized in the manufacturing and commercialization of cannabinoid-rich extracts from hemp and cannabis grown in Canada. A significant portion of these biomasses are certified Organic. The purified and standardized extracts rich in CBD and / or THC are sold in bulk or as finished products, such as tinctures, sprays and softgels. PurCann Pharma also offers R&D, extraction, purification and packaging services. The Company obtained its R&D license from Health Canada that allowed it to finalize and optimize its extraction-purification process, and its cannabis processing license that allows it to start the production. PurCann Pharma benefits from the facilities of SiliCycle Inc, located on a 165,000 ft² site in the Parc Technologique of Quebec City, Canada. The state-of-the-art factory built in 2009 was recently extended and now occupies more than 45,000 ft², including 9,000 ft² of laboratories and 20,000 ft² of manufacturing and packaging space - a $ 45 million total investment. The site is ISO 9001:2015 certified and Good Production Practices (“GMPs“), in accordance with Health Canada’s Cannabis Regulations, which are being established.For more information on PurCann, visit https://www.purcannpharma.com/ FORWARD-LOOKING STATEMENTS This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission and OTC Markets. CANAQUEST CONTACT:SILICYCLE CONTACT:Paul Ramsay, Co-Founder & PresidentHugo St-Laurent, Co-Founder, President & CEOCanaQuest Medical CorpPurCann Pharma, wholly owned subsidiary of SiliCycle Inc.paul@canaquest.com:Tel.: 416-704-3040 hugostlaurent@silicycle.comTel: 418-874-0054

  • GlobeNewswire

    CANAQUEST PRESIDENT INTERVIEWED BY THE WALL STREET ANALYZER

    TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to release a recent interview with company Co-founder and President, Paul Ramsay, on The Wall Street Analyzer, a multi-media financial research and publishing company reporting to the investment community on publicly held companies. It can be heard in full at: https://wallstreetanalyzer.com/2020/12/23/canaquest-medical-corp-otc-canqf/ Highlights in the discussion include significant milestones achieved by the Company: The Announcement that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of Mentabinol®, a patented THC based formulation & L-theanine - a safer alternative, for people who are taking THC for mental ailments, long-term pain, chemotherapy side-effects or reducing anxiety or depression. Mentabinol® could also be a viable treatment to help address and alleviate the opioid crisis. Second Master FormulationMentanine®, Omega-3 + CBD, non-psychotic - crosses the Blood Brain Barrier (BBB), CBD by itself, is not effective for mental health - does not cross the Blood Brain Barrier. Mentanine® has ~10x the efficacy of a CBD-based FDA-approved product by GW Pharma ($4B market cap) Looking to start clinical trials of Mentanine® as a treatment of epilepsy FDA-approval process expected to take 18 to 24 months Key difference vs other CBD products in the market - scientific formula supported by preclinical trials Company is looking to list on the CSE and up list in the US after a capital raise (currently on OTC Markets) Strong possibility for near term revenue, in advanced discussions with Licensed Processors and Distributors About CanaQuest Medical Corp: CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx and Mentabinol®Rx in Canada and the USA. As well, CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council. For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDgFor more information on CanaQuest, visit http://www.canaquest.com About Wall Street Analyzer: The Wall Street Analyzer http://www.wallstreetanalyzer.com/ is a multi-media financial research and publishing company reporting to the investment community on publicly held companies. FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission and OTC Markets. CANAQUEST CONTACT:Paul Ramsay, Co-Founder & President CanaQuest Medical Corppaul@canaquest.com:Tel.: 416-704-3040

  • CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE
    GlobeNewswire

    CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE

    CanaQuest Medical Corp MENTABINOL® SCIENTIFIC DISCOVERY AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCETORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of the Mentabinol®, a patented THC based formulation & L-theanine, a compound derived from Green Tea leaves. The Journal of Neuroscience, a world leading research publication, is a weekly peer-reviewed scientific journal published by the Society for Neuroscience. It covers empirical research on all aspects of neuroscience.This research showed that when the THC based formulation was combined with the compound L-theanine it protected rats against the negative side-effects that can result from straight THC.“What we found was that by administering L-theanine along with the THC based formulation, we were able to block several side effects of THC exposure, including changes to schizophrenia-related neurochemical pathways, and abnormalities in behaviors – including cognitive and emotional disturbances,” said Dr. Steven Laviolette, a professor at Western’s Schulich School of Medicine & Dentistry.“We started looking at L-theanine because there was strong evidence that it has neuroprotective properties, and previous studies haven’t shown any toxicity effects in humans or animals,” said Marta De Felice, PhD, a postdoctoral associate in Laviolette’s lab and first author on the study.“It was exciting to see the extent of those changes and we think this is really quite promising. The goal here is to produce a safer formulation for THC that is going to give the benefits without the negative psychiatric side effects. This will be especially beneficial for those who are taking THC for things like long-term pain, chemotherapy side-effects or reducing anxiety or depression.” said Laviolette.Western researchers believe this substance may mitigate this type of harm to chronic cannabis users. The team also concluded that their research provides evidence for combining the THC based formulations with L-theanine to make them safer for both recreational and medicinal use.Laviolette emphasizes that the University research took place in pre-clinical animal models and he looks forward to moving onto future human clinical trials to study and determine efficacy on humans.Paul Ramsay, CanaQuest’s President/Co-Founder, added, “We believe this important research discovery can help lead to a safer alternative for THC consumers, with our Mentabinol® product providing a viable treatment to help address and alleviate the opioid crisis.”About CanaQuest Medical Corp:CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, and his 13 team members, at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx and Mentabinol®Rx in Canada and the USA.CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science,” presented by the International Trade Council.For a copy of the Journal Article, visit The study was published in The Journal of Neuroscience. (jneurosci.org)For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDgFor more information on CanaQuest, visit http://www.canaquest.comAbout Dr. Steven Laviolette:The investigator leading the research is Dr. Steven Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University in London, Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status at Western University. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the top tier of neuroscience and psychiatry journals in the world. The following is a link to Dr. Laviolette’s profile on the Western University website. https://www.schulich.uwo.ca/about/news/2020/december/research_news_molecule_found_in_green_tea_may_block_negative_effects_of_chronic_cannabis_use.htmlFORWARD-LOOKING STATEMENTSThis news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission and OTC Markets.CANAQUEST CONTACT: Paul Ramsay, Co-Founder & President CanaQuest Medical Corp paul@canaquest.com: Tel.: 416-704-3040 Attachment * CanaQuest Medical Corp